Drug intelligence / Profile preview

WBP3425

Development stage: Unknown
Lead developer: Wuxi Zhikang Hongyi Biological Technology
Modality: Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
Administration: Intravenous

Overview

WBP3425 is a 4-1BB (CD137) agonist drug developed as an immunotherapy for cancer. It is being investigated primarily for the treatment of advanced malignant solid tumors. The drug acts by stimulating the 4-1BB receptor, a co-stimulatory molecule on T cells, thereby enhancing anti-tumor immune responses. WBP3425 is currently in Phase 1 clinical trials to evaluate its safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and preliminary anti-tumor activity in patients with advanced solid tumors. The developer and sponsor of these studies is Wuxi Zhikang Hongyi Biological Technology.

Targets

TNFRSF9 (CD137 extracellular domain)

Beyond the preview

Go deeper on WBP3425.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WBP3425.

Explore the full profile